Managed Entry Programs (MEPs) at VMD Sciences offer a strategic pathway to enhance market access for approved veterinary treatments that have yet to be adopted into routine practice, building on the foundation of our Managed Access Programs by providing a sponsored framework for broader integration. Through MEPs, we collaborate with pharmaceutical companies to enable veterinarians to gain hands-on experience with these approved therapies, allowing vets to integrate cutting-edge solutions into their practice while keeping treatment costs low for pet owners through sponsor-subsidized pricing. This structured access ensures that veterinarians can confidently adopt new treatments, building expertise and trust, while pet owners benefit from affordable, high-quality care that improves their animals’ quality of life.

For pharmaceutical companies, MEPs provide a powerful opportunity to collect Real-World Data (RWD) from participating animals, using VMD Sciences’ advanced technology platforms to monitor outcomes like clinical efficacy or owner-reported improvements in quality of life, complementing existing clinical study findings. This data supports development goals, accelerating global market penetration and reinforcing the treatment’s value proposition. Through MEPs, VMD Sciences marks a breakthrough in veterinary medicine, empowering veterinarians, reducing financial barriers for pet owners, and driving better outcomes for animals worldwide, all while helping sponsors achieve broader adoption and impact in the global veterinary landscape.